Nesina Patent Expiration

Can you believe NESINA received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(7 months from now)

US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6211205 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6329404 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6150383 TAKEDA PHARMS USA Pharmaceutical composition
Jun, 2016

(8 years ago)

US6303640 TAKEDA PHARMS USA Pharmaceutical composition
Aug, 2016

(7 years ago)

US6303661 TAKEDA PHARMS USA Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(7 years ago)

US6890898 TAKEDA PHARMS USA Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7078381 TAKEDA PHARMS USA Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7459428 TAKEDA PHARMS USA Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Dec, 2025

(1 year, 4 months from now)

US8697125 TAKEDA PHARMS USA Tablet preparation without causing a tableting trouble
Jun, 2029

(4 years from now)



Nesina is a drug owned by Takeda Pharmaceuticals Usa Inc. It is used for treating diabetes and associated disorders such as lipid and glucose metabolism issues. Nesina uses Alogliptin Benzoate as an active ingredient. Nesina was launched by Takeda Pharms Usa in 2013. It is is available in tablet form for oral use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 16, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 25, 2018
M(M-177) Apr 05, 2019
M(M-300) Jul 27, 2026

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ALOGLIPTIN BENZOATE ingredient

NCE-1 date: 25 January, 2017

Market Authorisation Date: 25 January, 2013

Treatment: Methods of reducing the amount of active components administered to a diabetic patient comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secr...

Dosage: TABLET

How can I launch a generic of NESINA before it's drug patent expiration?
More Information on Dosage

NESINA family patents

Family Patents